All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Center for Drug Evaluation, the most common co-covered peer. Source depth averages 10 original sources per story, versus 3.3 across the same-window beat baseline.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Xiao Ruiping
All 1 tracked stories fall under one category: market-trends. Of the tracked stories, 1 of 1 also mention Center for Drug Evaluation, the most common co-covered peer. Source depth averages 10 original sources per story, versus 3.3 across the same-window beat baseline. At 7, the average consequence score sits above the same-window beat average of 6.6. Xiao Ruiping appears in 1 tracked Healthcare story from March 25, 2026.
Stories tracked
1
Sources per story
10
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 26 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Xiao Ruiping. Shared-story counts are live from our verified record — not editorial picks.
Hope Medicine Inc. has initiated Phase III dosing for HMI-115, the first non-hormonal monoclonal antibody for endometriosis to reach this clinical stage. This milestone, supported by FDA Fast Track and NMPA Breakthrough designations, signals a potential shift away from traditional hormone-suppressing therapies in women's health.